의약품 시장 규모, 점유율, 동향 분석 보고서 : 분자 유형별, 제품별, 유형별, 질환별, 연령층별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Pharmaceutical Market Growth & Trends:

The global pharmaceutical market size is estimated to reach USD 2,350.43 billion by 2030, registering to grow at a CAGR of 6.12% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023, F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022, brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights:

• The Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
• The branded segment dominated the pharmaceutical market with a revenue share of 86.76% in 2024.
• The prescription segment dominated the market with a revenue share of 86.76% in 2024 due to rising demand for chronic disease treatments, technological advancements in drug development, and improved healthcare access.
• The cancer segment dominated the market with a revenue share of 18.06% in 2024.
• The oral segment dominated the peptide drug conjugates market with a revenue share of 57.53% in 2024 due to its convenience, patient compliance, and cost-effectiveness.
• The adults segment dominated the peptide drug conjugates market with a revenue share of 63.84% in 2024.
• The hospital pharmacy segment dominated the peptide drug conjugates market with a revenue share of 53.53% in 2024

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Advancement in therapeutics and robust product pipeline
    • 3.3.1.2. Rise in pharmaceutical r&d spending
    • 3.3.1.3. Rise in pharmaceutical r&d spending
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Patent expiration of key market drugs
    • 3.3.2.2. Pricing pressures on bio/pharmaceutical companies
    • 3.3.2.3. Stringent regulatory scenario
• 3.4. Dopamine Agonist Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape
• 3.5. Pipeline Analysis
  • 3.5.1. Phase 1
  • 3.5.2. Phase 2
  • 3.5.3. Phase 3

Chapter 4. Pharmaceutical Market: By Drug Estimates & Trend Analysis

• 4.1. Pharmaceutical Market: Drug Segment Dashboard
• 4.2. Pharmaceutical Market: By Drug Movement Analysis, USD Million, 2024 & 2030
• 4.3. Biologics & Biosimilars (Large Molecules)
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Monoclonal Antibodies
    • 4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Vaccines
    • 4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Cell & Gene Therapy
    • 4.3.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.5. Others
    • 4.3.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Conventional Drugs (Small Molecules)
  • 4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Market: Type Estimates & Trend Analysis

• 5.1. Pharmaceutical Market: Type Segment Dashboard
• 5.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
• 5.3. Prescription
  • 5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. OTC
  • 5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pharmaceutical Market: Product Estimates & Trend Analysis

• 6.1. Pharmaceutical Market: Product Segment Dashboard
• 6.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
• 6.3. Branded
  • 6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Generics
  • 6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmaceutical Market: Disease Estimates & Trend Analysis

• 7.1. Pharmaceutical Market: Disease Segment Dashboard
• 7.2. Pharmaceutical Market: By Disease Movement Analysis, USD Million, 2024 & 2030
• 7.3. Cardiovascular diseases
  • 7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Cancer
  • 7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Diabetes
  • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Infectious diseases
  • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Neurological disorders
  • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Respiratory diseases
  • 7.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Autoimmune diseases
  • 7.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.10. Mental health disorders
  • 7.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.11. Gastrointestinal disorders
  • 7.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.12. Women's Health Diseases
  • 7.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.13. Genetic and Rare genetic diseases
  • 7.13.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.14. Dermatological conditions
  • 7.14.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.15. Obesity
  • 7.15.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.16. Renal diseases
  • 7.16.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.17. Liver conditions
  • 7.17.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.18. Hematological disorders
  • 7.18.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.19. Eye conditions
  • 7.19.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.20. Infertility conditions
  • 7.20.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.21. Endocrine disorders
  • 7.21.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.22. Allergies
  • 7.22.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.23. Others
  • 7.23.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

• 8.1. Pharmaceutical Market: Route of Administration Segment Dashboard
• 8.2. Pharmaceutical Market: By Route of Administration Movement Analysis, USD Million, 2024 & 2030
• 8.3. Oral
  • 8.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. Tablets
  • 8.3.3. Capsules
  • 8.3.4. Suspensions
  • 8.3.5. Other
• 8.4. Topical
  • 8.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Parenteral
  • 8.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Intravenous
  • 8.5.3. Intramuscular
• 8.6. Inhalations
  • 8.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Other Routes of Administration
  • 8.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Pharmaceutical Market: Age Group Estimates & Trend Analysis

• 9.1. Pharmaceutical Market: Age Group Segment Dashboard
• 9.2. Pharmaceutical Market: By Age Group Movement Analysis, USD Million, 2024 & 2030
• 9.3. Children & Adolescents
  • 9.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Adults
  • 9.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Geriatric
  • 9.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis

• 10.1. Pharmaceutical Market: Distribution Channel Segment Dashboard
• 10.2. Pharmaceutical Market: By Distribution Channel Movement Analysis, USD Million, 2024 & 2030
• 10.3. Hospital Pharmacy
  • 10.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.4. Retail Pharmacy
  • 10.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.5. Others
  • 10.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Pharmaceutical Market: Regional Estimates & Trend Analysis

• 11.1. Pharmaceutical Market Share, By Region, 2024 & 2030, USD Million
• 11.2. North America
  • 11.2.1. North America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Regulatory Framework
    • 11.2.2.4. Reimbursement Framework
    • 11.2.2.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Regulatory Framework
    • 11.2.3.4. Reimbursement Framework
    • 11.2.3.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.2.4. Mexico
    • 11.2.4.1. Key Country Dynamics
    • 11.2.4.2. Target Disease Prevalence
    • 11.2.4.3. Regulatory Framework
    • 11.2.4.4. Reimbursement Framework
    • 11.2.4.5. Mexico Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.3. Europe
  • 11.3.1. Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.2. UK
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Regulatory Framework
    • 11.3.2.4. Reimbursement Framework
    • 11.3.2.5. Uk Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.3. Germany
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Regulatory Framework
    • 11.3.3.4. Reimbursement Framework
    • 11.3.3.5. Germany Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Regulatory Framework
    • 11.3.4.4. Reimbursement Framework
    • 11.3.4.5. France Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Regulatory Framework
    • 11.3.5.4. Reimbursement Framework
    • 11.3.5.5. Italy Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Regulatory Framework
    • 11.3.6.4. Reimbursement Framework
    • 11.3.6.5. Spain Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Regulatory Framework
    • 11.3.7.4. Reimbursement Framework
    • 11.3.7.5. Denmark Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Regulatory Framework
    • 11.3.8.4. Reimbursement Framework
    • 11.3.8.5. Sweden Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Regulatory Framework
    • 11.3.9.4. Reimbursement Framework
    • 11.3.9.5. Norway Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Regulatory Framework
    • 11.4.2.4. Reimbursement Framework
    • 11.4.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Regulatory Framework
    • 11.4.3.4. Reimbursement Framework
    • 11.4.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Regulatory Framework
    • 11.4.4.4. Reimbursement Framework
    • 11.4.4.5. India Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.5. Australia
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Regulatory Framework
    • 11.4.5.4. Reimbursement Framework
    • 11.4.5.5. Australia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.6. South Korea
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Regulatory Framework
    • 11.4.6.4. Reimbursement Framework
    • 11.4.6.5. South Korea Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Regulatory Framework
    • 11.4.7.4. Reimbursement Framework
    • 11.4.7.5. Thailand Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.5. Latin America
  • 11.5.1. Latin America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Regulatory Framework
    • 11.5.2.4. Reimbursement Framework
    • 11.5.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.5.3. Argentina
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Regulatory Framework
    • 11.5.3.4. Reimbursement Framework
    • 11.5.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.6. Middle East and Africa
  • 11.6.1. Middle East and Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Regulatory Framework
    • 11.6.2.4. Reimbursement Framework
    • 11.6.2.5. South Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Regulatory Framework
    • 11.6.3.4. Reimbursement Framework
    • 11.6.3.5. Saudi Arabia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.4. UAE
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Regulatory Framework
    • 11.6.4.4. Reimbursement Framework
    • 11.6.4.5. UAE Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Regulatory Framework
    • 11.6.5.4. Reimbursement Framework
    • 11.6.5.5. Kuwait Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Recent Developments & Impact Analysis by Key Market Participants
• 12.2. Company Categorization
• 12.3. Participant Overview
• 12.4. Financial Performance
• 12.5. Product Bench Marking
• 12.6. Company Market Share Analysis, 2024
• 12.7. Company Profiles
  • 12.7.1. F. Hoffmann-La Roche Ltd
    • 12.7.1.1. Participant's Overview
    • 12.7.1.2. Financial Performance
    • 12.7.1.3. Product Benchmarking
    • 12.7.1.4. Recent Developments/ Strategic Initiatives
  • 12.7.2. Novartis AG
    • 12.7.2.1. Participant's Overview
    • 12.7.2.2. Financial Performance
    • 12.7.2.3. Product Benchmarking
    • 12.7.2.4. Recent Developments/ Strategic Initiatives
  • 12.7.3. AbbVie Inc.
    • 12.7.3.1. Participant's Overview
    • 12.7.3.2. Financial Performance
    • 12.7.3.3. Product Benchmarking
    • 12.7.3.4. Recent Developments/ Strategic Initiatives
  • 12.7.4. Johnson & Johnson Services, Inc.
    • 12.7.4.1. Participant's Overview
    • 12.7.4.2. Financial Performance
    • 12.7.4.3. Product Benchmarking
    • 12.7.4.4. Recent Developments/ Strategic Initiatives
  • 12.7.5. Merck & Co., Inc.
    • 12.7.5.1. Participant's Overview
    • 12.7.5.2. Financial Performance
    • 12.7.5.3. Product Benchmarking
    • 12.7.5.4. Recent Developments/ Strategic Initiatives
  • 12.7.6. Pfizer Inc.
    • 12.7.6.1. Participant's Overview
    • 12.7.6.2. Financial Performance
    • 12.7.6.3. Product Benchmarking
    • 12.7.6.4. Recent Developments/ Strategic Initiatives
  • 12.7.7. Bristol-Myers Squibb Company
    • 12.7.7.1. Participant's Overview
    • 12.7.7.2. Financial Performance
    • 12.7.7.3. Product Benchmarking
    • 12.7.7.4. Recent Developments/ Strategic Initiatives
  • 12.7.8. Sanofi
    • 12.7.8.1. Participant's Overview
    • 12.7.8.2. Financial Performance
    • 12.7.8.3. Product Benchmarking
    • 12.7.8.4. Recent Developments/ Strategic Initiatives
  • 12.7.9. GlaxoSmithKline plc.
    • 12.7.9.1. Participant's Overview
    • 12.7.9.2. Financial Performance
    • 12.7.9.3. Product Benchmarking
    • 12.7.9.4. Recent Developments/ Strategic Initiatives
  • 12.7.10. AstraZeneca
    • 12.7.10.1. Participant's Overview
    • 12.7.10.2. Financial Performance
    • 12.7.10.3. Product Benchmarking
    • 12.7.10.4. Recent Developments/ Strategic Initiatives
  • 12.7.11. Takeda Pharmaceutical Co., Ltd.
    • 12.7.11.1. Participant's Overview
    • 12.7.11.2. Financial Performance
    • 12.7.11.3. Product Benchmarking
    • 12.7.11.4. Recent Developments/ Strategic Initiatives

Chapter 13. Conclusion